Bristol Myers Squibb Building Life Science Industry’s Most Advanced AI Factory on NVIDIA Vera Rubin
BMS scales its AI infrastructure with a second NVIDIA DGX SuperPOD to accelerate drug discovery and research.
Erin Davis calls it the “SuperDuperPOD.” That’s two things in one name: pharmaceutical giant Bristol Myers Squibb (BMS) already runs one of the largest AI clusters in life sciences, with serious results to show for it. And they’re doubling down. BMS announced today it is deployin...
NVIDIA Blog
Source

Generated insight by OnAirToday AI
Bristol Myers Squibb's investment in dedicated AI supercomputing infrastructure demonstrates a critical shift toward accelerating drug discovery timelines through massive-scale generative modeling. By leveraging high-performance computing clusters, the company is effectively industrializing pharmaceutical R&D to reduce the time and cost required to bring life-saving therapies to market.

Comments
Keep comments relevant and respectful. No links, advertising, self-promotion, or spam.